Review
Oct 2026
BACKGROUND
Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...
Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al.
· New England Journal of Medic... · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Review
Open access
Oct 2026
PURPOSE
MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...
Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al.
· Journal of Clinical Oncology · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓
Open access
Sep 2026
Findings suggest that Eva-1 homolog B contributes to NSCLC progression and may act, at least in part, through an LRG1-related mechanism.
Zhang-Zhou Huang, Hai-Bo Wang, K. Jiang et al.
· 3 Biotech · 0 citations
Save
{ copied = true; setTimeout(() => copied = false, 1500) })"
class="icon-btn" aria-label="Copy link">
{ copied = 'apa'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy APA
Copied ✓
{ copied = 'mla'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy MLA
Copied ✓
{ copied = 'bibtex'; setTimeout(() => { copied = null; open = false }, 1000) })"
class="flex w-full items-center justify-between rounded-lg px-3 py-2 text-left text-sm hover:bg-gray-100 dark:hover:bg-ink-800">
Copy BibTeX
Copied ✓